These findings suggest that taVNS may mitigate neuronal damage and improve depression-like behaviors by inhibiting excessive activation of the NF-κB/TNF-α pathway in both the prefrontal cortex and peripheral systems. Here, NFKB1 is linked to depressive symptom measurement.